Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H4TP
|
|||
| Former ID |
DNC002343
|
|||
| Drug Name |
GSK189254A
|
|||
| Synonyms |
720690-73-3; GSK 189254A; GSK-189254; GSK189254A; UNII-5T4TX6CO53; GSK189254; CHEMBL517140; 5T4TX6CO53; 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide; 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide; WROHEWWOCPRMIA-UHFFFAOYSA-N; 854485-15-7; GSK-189254A; SCHEMBL169579; ZINC3961799; AOB87474; EX-A1905; ABP000814; BDBM50247054; AKOS032944981; CS-6206; BCP9000737; GSK-189,254; KB-77605; HY-14111
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Investigative | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H25N3O2
|
|||
| Canonical SMILES |
CNC(=O)C1=CN=C(C=C1)OC2=CC3=C(CCN(CC3)C4CCC4)C=C2
|
|||
| InChI |
1S/C21H25N3O2/c1-22-21(25)17-6-8-20(23-14-17)26-19-7-5-15-9-11-24(18-3-2-4-18)12-10-16(15)13-19/h5-8,13-14,18H,2-4,9-12H2,1H3,(H,22,25)
|
|||
| InChIKey |
WROHEWWOCPRMIA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 720690-73-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Antagonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.